Neuphoria Therapeutics Adopts Limited-Duration Stockholder Rights Plan to Protect Integrity of Process
BURLINGTON, Mass., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. ("Neuphoria" or the "Company") (NASDAQ:NEUP), a clinical-stage biotechnology company developing impactful treatments for neuropsychiatric disorders, today announced that its Board of Directors (the "Board") has determined to adopt a limited-duration stockholder rights plan (the "Rights Plan"), effective immediately. The Board adopted the Rights Plan in response to significant and rapid accumulations of the Company's publicly traded common stock by certain investors. The Rights Plan is intended to protect the interests of the Company and its stockholders, help ensure that all interested parties have the oppo
